loader2
Login Open ICICI 3-in-1 Account
Text Size
Text to Speech
Color Contrast
Pause Animations
IPOLogoImag

SAI PARENTERAL'S IPO

UPCOMING

IPO Details

24th Mar 2026
27th Mar 2026
38
₹ 14,136
₹ 372-392
₹ 409 Crore

Issue timeline

  • 24-27 Mar 2026
  • 30-Mar-2026
  • 01-Apr-2026
  • 01-Apr-2026
  • 02-Apr-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Sai Parenterals Limited specializes in the development and manufacture of pharmaceutical formulations across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic agents, respiratory health, antibiotics, and dermatology. The company owns and operates five manufacturing facilities in India—four in Hyderabad, Telangana, and one in Ongole, Andhra Pradesh. Its facilities hold various accreditations, including WHO-GMP, TGA-Australia, and PIC/S.

The company serves a customer base of government departments, public and private sector hospitals, and pharmaceutical companies. Since entering the export market in FY23, the company has expanded its presence to regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa. Through its Singapore subsidiary, the company has also entered into the acquisition of Noumed Pharmaceuticals Pty Limited in Australia.

2001
Anil Kumar Karusala

Objectives

Funding the expansion and upgradation of manufacturing facilities (₹110.8 crore).
Establishment of a new Research and Development Centre (₹18.02 crore).
Repayment or prepayment of certain outstanding borrowings (₹14.3 crore).
Meeting the working capital requirements of the company (₹33 crore).
Investment in Sai Parenterals Pte Limited (Singapore) for the acquisition of Noumed Pharmaceuticals Pty Limited (₹35.6 crore).
General corporate purposes.

Strengths & Risks

Strengths (4)

Diversified Product Portfolio: Capabilities across various therapeutic areas and multiple dosage forms, including sterile injectables.

Risks (4)

Geographical Concentration: Four out of five manufacturing facilities are located in Hyderabad, Telangana, making operations vulnerable to regional disruptions.

Financials

Industry Overview

  • Market Scale & Growth: The Indian pharmaceutical industry, valued at $62 billion in 2025, is the third largest globally by volume and is projected to reach $146 billion by 2033, growing at a robust CAGR of 11.2%.
  • Sector Evolution: The market is shifting toward complex generics, biosimilars, and chronic care therapies, with the domestic drug formulation segment alone expected to more than double to $109 billion by 2033.
  • CDMO Integration: Indian Contract Development and Manufacturing Organisations (CDMOs) are expanding their role across the entire value chain, from drug discovery to commercialization, to meet evolving global pharmaceutical demands.
Comparison with Listed Industry Peers for FY25 as per RHP
Name of the Company

EPS(₹)

P/E Ratio (x) 

Return on Net Worth (RoNW)

Sai Parenteral's Limited
5.43 NA 15.09%
Sai Life Sciences Limited
8.83 107.7 7.99%
Innova Captab Limited
22.41 32.45 13.37%
Senores Pharmaceuticals Limited
16.12 64.3 7.18%
Gland Pharma Limited
42.4 44.71 7.63%

Sai Parenteral's IPO FAQs

What is the Sai Parenteral's IPO date?

The Sai Parenteral's IPO is scheduled to open for public subscription on March 24, 2026, and close on March 27, 2026.

The price band for Sai Parenteral's IPO has been fixed in the range of ₹372 to ₹392 per equity share.

The minimum lot size for Sai Parenteral's IPO is 38 equity shares, requiring an investment of ₹14,136 at the upper price band.

The promoters of the company are Anil Kumar Karusala, Vijitha Gorrepati, and Karusala Aruna.

The shares are proposed to be listed on the BSE and NSE.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.